Pro-Dex (NASDAQ:PDEX) Shares Cross Below 200-Day Moving Average - Should You Sell?

Shares of Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $46.51 and traded as low as $39.61. Pro-Dex shares last traded at $40.27, with a volume of 136,676 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Pro-Dex from a "hold" rating to a "buy" rating in a research report on Tuesday.

Pro-Dex Stock Performance

The company has a market cap of $140.61 million, a P/E ratio of 21.45 and a beta of 0.37. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $53.45 and a two-hundred day simple moving average of $46.55.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.98 EPS for the quarter, beating the consensus estimate of $0.47 by $0.51. The firm had revenue of $17.41 million during the quarter, compared to analyst estimates of $17.70 million. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, sell-side analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Insider Buying and Selling at Pro-Dex

In other news, Director Raymond E. Cabillot sold 7,674 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $45.00, for a total transaction of $345,330.00. Following the completion of the sale, the director now owns 310,978 shares of the company's stock, valued at $13,994,010. The trade was a 2.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 21,383 shares of company stock valued at $1,031,182. Insiders own 47.50% of the company's stock.

Hedge Funds Weigh In On Pro-Dex

Institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new stake in Pro-Dex during the first quarter valued at about $170,000. Bank of New York Mellon Corp purchased a new position in shares of Pro-Dex during the 4th quarter valued at about $202,000. Trexquant Investment LP bought a new position in shares of Pro-Dex during the 4th quarter valued at approximately $252,000. Integrated Quantitative Investments LLC bought a new position in shares of Pro-Dex during the 4th quarter valued at approximately $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Pro-Dex in the 4th quarter worth approximately $255,000. 15.28% of the stock is owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.